Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC
What is the purpose of this trial?
To investigate whether PF-05212384 in combination with irinotecan is superior to cetuximab in combination with irinotecan in prolonging PFS in patients with KRAS and NRAS wild type mCRC who have progressed following prior treatment with irinotecan, oxaliplatin, and fluoropyrimidine.
- 18 Years and older
- Pfizer Inc., U.S. Pharmaceuticals Group
- Last Updated:
- Study HIC#: